Michelle Gilson
Stock Analyst at Morgan Stanley
(1.13)
# 3,770
Out of 5,165 analysts
32
Total ratings
34.48%
Success rate
-6.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Maintains: Overweight | $20 → $24 | $9.68 | +148.06% | 5 | Feb 24, 2026 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $32.18 | -6.77% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $2.49 | +582.73% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $231.03 | -15.16% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $28.03 | +60.54% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $33.96 | +123.79% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $57.43 | +58.45% | 12 | Mar 1, 2021 |
Vir Biotechnology
Feb 24, 2026
Maintains: Overweight
Price Target: $20 → $24
Current: $9.68
Upside: +148.06%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $32.18
Upside: -6.77%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $2.49
Upside: +582.73%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $231.03
Upside: -15.16%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $28.03
Upside: +60.54%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $33.96
Upside: +123.79%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $57.43
Upside: +58.45%